Genenta Closes Its Upsized Initial Public Offering of American Depository Shares
On December 17, 2021, Genenta Science (Nasdaq: GNTA) announced the completion of its upsized initial public offering, raising approximately $36 million by selling 2.4 million ADSs at $11.50 each, along with 720,114 ordinary shares to existing shareholders. The offering began trading on December 15, 2021. Roth Capital Partners and Maxim Group are involved in managing the offering. Additionally, the underwriters have a 30-day option to purchase an additional 360,000 ADSs, potentially increasing the total proceeds to around $40 million.
- Successfully raised approximately $36 million through IPO.
- Initial public offering includes shares for existing shareholders.
- Potential for additional $4 million if underwriters exercise their option.
- Dilution risk for existing shareholders due to new share issuances.
- -
MILAN, Italy and NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™, announced today the closing of its upsized initial public offering of 2.4 million American Depositary Shares (“ADSs”) at a public offering price of
Roth Capital Partners acted as sole book-running manager of the offering. Maxim Group LLC acted as lead manager of the offering.
Genenta has granted the underwriters an option for a period of 30 days from the date of the final prospectus to purchase an additional 360,000 ADSs, which, if exercised, the gross proceeds from the offering will be approximately
A Registration Statement on Form F-1 relating to these securities became effective on December 14, 2021. The offering is made only by means of a prospectus forming a part of the effective Form F-1 Registration Statement, copies of which may be obtained from Roth Capital Partners, 888 San Clemente Drive, Newport Beach, CA 92660, Attention: Equity Capital Markets at (800) 678-9147 or by email at rothecm@roth.com; or from Maxim Group LLC at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or by telephone at (212) 895-3745 or by email at syndicate@maximgrp.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Genenta Science
Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
| Investor Relator - LifeSci Advisors: Mary-Ann Chang, CFA +44 7483 28 48 53 mchang@lifesciadvisors.com | Genenta Media/Investor Contact Stefania Mazzoleni, PhD +39 339 709 59 31 stefania.mazzoleni@genenta.com |
FAQ
What is the significance of Genenta Science's IPO on December 17, 2021?
What is the public offering price for Genenta Science's shares?
When did Genenta Science start trading on the Nasdaq?
What are the potential additional proceeds from the IPO?
What does the IPO mean for existing shareholders of GNTA?
